Drugs / ATG
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT03818334 Comparator | Nov 2018 → Nov 2021 overdue | bone marrow disorder, graft versus host disease, immunodeficiency disease, viral infectious disease | Hospital Israelita Albert Einstein | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATG | “Thymoglobulin (ATG)” NCT03818334 ↗ |
| Modality | Protein / enzyme biologic | “Antihuman T-Lymphocyte Immune Globulin 25 mg/flask” NCT03818334 ↗ |